Insmed (NASDAQ:INSM) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of Insmed (NASDAQ:INSM) to a moderate buy rating in a report released on Thursday morning,Zacks.com reports.

Other analysts have also issued research reports about the company. Royal Bank Of Canada upped their price objective on Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. HC Wainwright upped their price objective on Insmed from $230.00 to $245.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Jefferies Financial Group assumed coverage on Insmed in a research report on Monday, March 16th. They set a “buy” rating and a $228.00 price objective on the stock. Barclays boosted their target price on shares of Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Finally, Bank of America boosted their target price on shares of Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Insmed currently has a consensus rating of “Buy” and an average price target of $212.09.

Insmed Stock Down 3.0%

Insmed stock opened at $154.81 on Thursday. Insmed has a twelve month low of $63.81 and a twelve month high of $212.75. The stock’s fifty day simple moving average is $150.47 and its 200-day simple moving average is $167.20. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $33.42 billion, a P/E ratio of -24.15 and a beta of 1.10.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The company had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. During the same period in the prior year, the company posted ($1.32) EPS. The firm’s revenue was up 152.6% compared to the same quarter last year. As a group, equities analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO William Lewis sold 19,215 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the completion of the transaction, the chief executive officer owned 306,891 shares in the company, valued at approximately $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Michael Alexander Smith sold 19,638 shares of the business’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the transaction, the insider owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. The trade was a 27.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 198,992 shares of company stock worth $31,660,112. Corporate insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

Institutional investors and hedge funds have recently modified their holdings of the company. Norges Bank acquired a new position in Insmed in the fourth quarter valued at $506,625,000. Vanguard Group Inc. boosted its stake in Insmed by 13.0% in the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after acquiring an additional 2,291,328 shares in the last quarter. RTW Investments LP boosted its stake in Insmed by 57.0% in the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after acquiring an additional 1,758,321 shares in the last quarter. Artisan Partners Limited Partnership boosted its stake in Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after acquiring an additional 1,623,342 shares in the last quarter. Finally, Orbis Allan Gray Ltd acquired a new position in Insmed in the second quarter valued at $153,389,000.

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Raymond James initiated coverage with an “Outperform” rating and a $200 price target, providing a near‑term upside anchor for the stock. The Fly
• Positive Sentiment: HC Wainwright updated its multi‑year model: it cut FY2030 EPS but materially raised FY2027–FY2029 estimates (FY2027 to $0.88, FY2028 to $3.38, FY2029 to $6.15), and maintains a $245 price objective — signaling improving medium‑term profitability assumptions from a major biotech analyst. MarketBeat: HC Wainwright updates
• Positive Sentiment: Large institutional holders (including Norges Bank and Vanguard) have built meaningful positions recently, which supports a structural bid under the stock and reduces free‑float supply pressure. MarketBeat: Institutional holdings
• Neutral Sentiment: Coverage pieces and valuation debates (e.g., “Is it too late to consider Insmed?”) are circulating; these frame the stock as recovery vs. valuation trade and may amplify headline trading but don’t change fundamentals on their own. Yahoo: Is it too late?
• Neutral Sentiment: CEO William Lewis sold 10,699 shares under a pre‑arranged Rule 10b5‑1 plan; the sale is material in dollar terms but was preplanned and follows a pattern of scheduled dispositions. SEC Form 4
• Negative Sentiment: Short interest rose sharply in March (roughly a 37% increase to ~13.8M shares, ~6.6% of the float, ~4.7 days to cover), raising downside pressure from bearish bets and amplifying volatility on negative headlines.
• Negative Sentiment: Insmed will discontinue development of brensocatib for hidradenitis suppurativa after the Phase 2b CEDAR trial missed primary/secondary endpoints (placebo outperformed), removing that potential revenue stream and driving the recent selloff and a trading halt on the study news. Reuters: Program discontinued
• Negative Sentiment: Market reaction to the trial miss included a trading halt and sharp intraday declines, signaling elevated near‑term downside risk and headline sensitivity. Investing.com: Market reaction

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.